Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, Clinical Data, Specialty Laboratories, Celera Genomics, PerkinElmer, SoftGenetics, Beckman Coulter, DNAPrint, CombiSep, BioDiscovery

Sequenom last week said it has launched the latest generation of its multiplex genotyping product, the iPLEX Gold assay.
The assay enables a typical fine mapping genotyping study for about 3 1/2 cents per data point by providing routine multiplexing at 36 times per reaction and, depending upon the complexity of the specific assay, up to 40 times per reaction, which represents customer savings of approximately 25 percent per study compared to the original iPLEX assay and improves project efficiency, according to Sequenom.

Clinical Data’s PGxHealth division has launched PGxTest:Warfarin, a pharmacogenetic test that assists physicians in detemining warfarin dosing requirements by measuring variation in two genes: CYP2C9, which metabolizes warfarin; and VKORC1, which encodes the enzyme that is the target of warfarin. Clinicians and payors may request prescribing information by calling 1-888-5-warfarin or going to, the company said.
“The results of this test, when used in combination with other important clinical information, should reduce the guesswork in dose selection and enable more precise determination of the final dosing regimen," said Carol Reed, senior vice president and chief medical officer of Clinical Data, in a statement.
The company noted that the use of the test “does not eliminate the need for monitoring prothrombin times as clinically indicated.”

Specialty Laboratories has launched HCV Liver Fibrosis GenotypR, a genomic clinical test to predict progression to liver fibrosis or cirrhosis for hepatitis C virus patients.
The test identifies a patient's genomic signature for seven SNPs to provide a “Cirrhosis Risk Score,” which rates the relative risk of progression to liver fibrosis or cirrhosis, the company said. This score places a patient into one of four risk groups in order to assist physicians in determining those who may need early therapy.
Specialty Laboratories developed the test under an intellectual property license from Celera Genomics.

PerkinElmer has released the Comprehensive Solution Autoplex Gene Expression Platform and the Spectral Genomics Array Comparative Genomic Hybridization Platform.
The CS Autoplex Platform includes two products for gene expression validation: a custom gene-expression panel kit and a labeling kit, both with analysis software. The kits are built upon Luminex's xMAP technology.
The Spectral Genomics Array CGH Platform, meanwhile, is a BAC-based system that includes the SpectralChip 2600 array, the Constitutional Chip 3.0 array, the ScanArray system, labeling reagents, and SpectralWare analysis software. The company said that the system can generate results in 24 hours, rather than the “industry standard of five to 20 days in the lab, which is common for standard karyotyping.”

SoftGenetics has released a new module for its GeneMarker software for MLPA (multiplex ligation-dependent probe amplification) analysis using Luminex xMap technology. The software, developed in collaboration with the Mayo Clinic and Foundation, detects exon copy number changes associated with breast and colon cancers, as well as trisomies found in Down syndrome. GeneMarker Luminex-MLPA automatically performs background subtraction and flags suspect intensities according to user-specified thresholds, the company said. The software selects the least variable sample from the sample set to act as the reference for determining copy number change.

Beckman Coulter has released Biomek 3000 GeXP, a software plug-in for automated gene expression sample preparation for the GenomeLab GeXP Genetic Analysis system on the Biomek 3000 Liquid Handling Workstation. The suite includes methods for RNA sample prep, quantitation, and normalization and reaction setup. 

DNAPrint subsidiary Ellipsis Biotherapeutics has launched several new genotyping services. One, for whole-genome association studies, uses custom and standard panels for Illumina’s GoldenGate platform. The second service is based on an expanded version of the Beckman Coulter SNPstream platform to encompass 48-plex capacity.

CombiSep has released Oligo PRO, a system for performing DNA and RNA oligonucleotide purity analysis. The system determines the relative purity of 96 different samples in parallel using capillary gel electrophoresis with UV absorbance detection. It includes data-analysis software that provides automatic and manual peak integration and report generation. 

BioDiscovery this week released a new array comparative genomic hybridization module for its Imagene 7.0 software. Imagene can now provide array-based DNA copy number analysis and visualization of DNA gains and losses.
According to BioDiscovery, its aCGH module features a statistical algorithm based on the circular binary segmentation approach and “eliminates the need for knowledge of advanced scripting languages or statistical settings.”

Filed under

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.